ARK Invest's position in RXRX, updated every trading day. Data as of 2026-11-12.
| Fund | Shares | Value | Weight | Rank |
|---|---|---|---|---|
| ARKK | 30,904,722 | $102.9M | 1.41% | #25 |
| ARKG | 16,380,531 | $54.5M | 2.76% | #14 |
| Trade day | Fund | Side | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-15 | ARKK | Buy | Added | 3,208,315 | $13.3M |
| 2026-10-15 | ARKG | Buy | Added | 1,021,920 | $4.3M |
| 2026-10-07 | ARKK | Buy | Added | 1,524,723 | $6.5M |
| 2026-10-07 | ARKG | Buy | Added | 355,344 | $1.5M |
| 2026-10-06 | ARKK | Buy | Added | 271,172 | $1.3M |
| 2026-10-06 | ARKG | Buy | Added | 69,145 | $320K |
| 2026-10-05 | ARKK | Buy | Added | 1,189,265 | $5.7M |
| 2026-10-05 | ARKG | Buy | Added | 293,092 | $1.4M |
| 2026-07-14 | ARKG | Buy | Added | 14,897 | $50K |
| 2026-07-13 | ARKK | Buy | Added | 84,052 | $277K |
| 2026-07-13 | ARKG | Buy | Added | 48,320 | $159K |
| 2026-07-10 | ARKK | Buy | Added | 157,273 | $560K |
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis;…
See RXRX's full ARK history since 2024, ARK's estimated cost basis, the conviction score and buy/sell alerts.
Open RXRX on FundWake →Data comes from ARK Invest's public daily holdings and trade files. FundWake is not affiliated with ARK Invest. Nothing here is investment advice.